Global Personalized Tumor Vaccines Market Growth (Status and Outlook) 2025-2031
Description
The global Personalized Tumor Vaccines market size is predicted to grow from US$ 155 million in 2025 to US$ 229 million in 2031; it is expected to grow at a CAGR of 6.7% from 2025 to 2031.
Personalized tumor vaccines are a type of customized immunotherapy based on a patient's individual tumor-specific antigens, designed to activate the patient's own immune system to accurately identify and attack tumor cells. Through genome sequencing and bioinformatics analysis, scientists are able to identify unique mutations (i.e., neoantigens) in tumor cells and design and synthesize vaccines targeting these neoantigens.
United States market for Personalized Tumor Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Personalized Tumor Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Personalized Tumor Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Personalized Tumor Vaccines players cover Geneos Therapeutics, BioNTech, Siemens, Moderna, Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Personalized Tumor Vaccines Industry Forecast” looks at past sales and reviews total world Personalized Tumor Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected Personalized Tumor Vaccines sales for 2025 through 2031. With Personalized Tumor Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Personalized Tumor Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Personalized Tumor Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Personalized Tumor Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Personalized Tumor Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Personalized Tumor Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Personalized Tumor Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Personalized Tumor Vaccines market by product type, application, key players and key regions and countries.
Segmentation by Type:
DNA-based
RNA-based
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Geneos Therapeutics
BioNTech
Siemens
Moderna
Merck
Everest Medicines
Please note: The report will take approximately 2 business days to prepare and deliver.
Personalized tumor vaccines are a type of customized immunotherapy based on a patient's individual tumor-specific antigens, designed to activate the patient's own immune system to accurately identify and attack tumor cells. Through genome sequencing and bioinformatics analysis, scientists are able to identify unique mutations (i.e., neoantigens) in tumor cells and design and synthesize vaccines targeting these neoantigens.
United States market for Personalized Tumor Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Personalized Tumor Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Personalized Tumor Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Personalized Tumor Vaccines players cover Geneos Therapeutics, BioNTech, Siemens, Moderna, Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Personalized Tumor Vaccines Industry Forecast” looks at past sales and reviews total world Personalized Tumor Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected Personalized Tumor Vaccines sales for 2025 through 2031. With Personalized Tumor Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Personalized Tumor Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Personalized Tumor Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Personalized Tumor Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Personalized Tumor Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Personalized Tumor Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Personalized Tumor Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Personalized Tumor Vaccines market by product type, application, key players and key regions and countries.
Segmentation by Type:
DNA-based
RNA-based
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Geneos Therapeutics
BioNTech
Siemens
Moderna
Merck
Everest Medicines
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
82 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Personalized Tumor Vaccines Market Size by Player
- 4 Personalized Tumor Vaccines by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Personalized Tumor Vaccines Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
